1. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Issue 6 (June 2020) Authors: Janjigian, Yelena Y; Maron, Steven B; Chatila, Walid K; Millang, Brittanie; Chavan, Shweta S; Alterman, Carly; Chou, Joanne F; Segal, Michal F; Simmons, Marc Z; Momtaz, Parisa; Shcherba, Marina; Ku, Geoffrey Y; Zervoudakis, Alice; Won, Elizabeth S; Kelsen, David P; Ilson, David H; Nagy, Rebecca J... Journal: Lancet oncology Issue: Volume 21:Issue 6(2020) Page Start: 821 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗